Optimi Health Corp(OPTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.93 | Insider Own | 19.32% | Shs Outstand | 5.7M | Perf Week | -5.26% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.6M | Perf Month | -3.85% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.13 | Inst Own | 7.75% | Short Float | 0.38% | Perf Quarter | -3.64% |
| Income | -0.00B | P/S | 66.12 | EPS this Y | - | Inst Trans | 32.79% | Short Ratio | 0.23 | Perf Half Y | -31.76% |
| Sales | 0.00B | P/B | 2.07 | EPS next 5Y | - | ROA | -27.66% | Short Interest | 0.02M | Perf YTD | -34.33% |
| Book/sh | 2.17 | P/C | 2.8 | EPS past 3/5Y | 27.91% -72.14% | ROE | -43.87% | 52W High | -49.08% ($8.84) | Perf Year | -23.08% |
| Cash/sh | 1.61 | P/FCF | - | Sales past 3/5Y | 68.99% - | ROIC | -23.59% | 52W Low | 12.5% ($4.00) | Perf 3Y | 7.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 34.45% | Gross Margin | -324.4% | Volatility(W/M) | 6.37% 5.08% | Perf 5Y | -69.63% |
| Dividend TTM | - | EV/Sales | 51.81 | Sales Y/Y TTM | 61.11% | Oper. Margin | -824.18% | ATR (14) | 0.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.69 | EPS Q/Q | -842.19% | Profit Margin | -751.47% | RSI (14) | 41.04 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.73 | Sales Q/Q | 137.27% | SMA20 | -6.43% ($4.81) | Beta | 1.3 | Target Price | - |
| Payout | - | Debt/Eq | 0.29 | Earnings | 2026/8/14 | SMA50 | -5.96% ($4.79) | Rel Volume | 2.11 | Prev Close | $4.35 |
| Employees | - | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -43.14% -34.88% | SMA200 | -27.67% ($6.22) | Avg Volume(3M) | 0.08M | Price | $4.5 |
| IPO | 2026/5/20 | Option/Short | No/Yes | Trades | 581 | Volume | 161,436 | Change | 3.45% |
Company
OPTH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Optimi Health (OPTH) is a Canada-based pharmaceutical manufacturer specializing in strict pharmaceutical-grade production of psychedelic medicines. It holds a relatively rare commercial-scale manufacturing capability for producing botanical psilocybin and MDMA legally for medical use, supplying these to regulated-permitted markets such as Australia and Canada.
Over the past 1 year, on the lower side
49% below its 1-year high.
OPTH has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Would have changed by +8.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 7.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSIL 0.01%It ranks #4 in the industry
Based on market cap of $26M.
OPTH $26M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is OPTH?
OPTH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of OPTH?
The market cap of OPTH is approximately $26M, ranking 5,205 within its sector.
What is the 52-week high and low for OPTH?
OPTH has recorded a 52-week high of $8.84 and a low of $4.00.
